Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy.

Trial Profile

Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Intervertebral disc degeneration; Spinal disorders
  • Focus Adverse reactions
  • Sponsors Bioinova
  • Most Recent Events

    • 24 Sep 2017 Status changed from recruiting to discontinued.
    • 15 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top